8 completed, 4 unknown, 1 active not recruiting, 1 not yet recruiting. 14 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 8, Unknown 4, Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Postmenopausal Osteoporosis: new trials by email Literature Review of Postmenopausal Osteoporosis trials Research Report on Postmenopausal Osteoporosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass Denosumab, Placebo - Postmenopausal Osteoporosis, Low Bone Mass | Phase 2 | Not yet recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 110 | 2026-10-31 | 2026-09-11 |
| A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) AGA2118, Placebo - Postmenopausal Osteoporosis | Phase 2 | Active not recruiting | Angitia Biopharmaceuticals | 379 | 2024-10-31 | 2026-02-10 |
| Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis JMT103, Denosumab, Placebo - Postmenopausal Osteoporosis | Phase 2 | Unknown | Shanghai JMT-Bio Inc. | 200 | 2022-04-21 | 2022-07-18 |
| G56W1 in Women With Postmenopausal Osteoporosis rhPTH(1-34) 28.2μg, rhPTH(1-34) 56.5μg, teriparatide acetate(Teribone™) - Postmenopausal Osteoporosis | Phase 1 / Phase 2 | Unknown | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 148 | 2018-10-01 | 2018-10-25 |
| The Deferasirox-calcium-vitamin D3 Therapy for Postmenopausal Osteoporosis (PMOP) Deferasirox and calcium-vitamin D3, Calcium-vitamin D3 - Postmenopausal Osteoporosis | Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 10 | 2018-01-15 | 2018-05-17 |
| Molecular Mechanism of POP Kidney Yin Deficiency Syndrome From the Interventional Effects of CLCF1 Liuwei Dihuang Pills - Postmenopausal Osteoporosis | Phase 2 | Unknown | Fujian Academy of Traditional Chinese Medicine | 25 | 2012-01-01 | 2013-04-18 |
| Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women PTH analog, Placebo, Forsteo (Teriparatide) - Postmenopausal Osteoporosis | Phase 2 | Completed | Unigene Laboratories Inc. | 97 | 2011-02-01 | 2013-03-01 |
| MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012) MK-5442, Placebo to MK-5442, Alendronate Sodium - Osteoporosis, Postmenopausal Osteoporosis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 526 | 2009-11-01 | 2016-01-22 |
| Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density Placebo to Romosozumab, Alendronate, Teriparatide - Low Bone Mineral Density, Postmenopausal Osteoporosis | Phase 2 | Completed | Amgen | 419 | 2009-06-03 | 2022-09-22 |
| A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab Previous denosumab - Low Bone Mass, Low Bone Mineral Density | Phase 2 | Completed | Amgen | 15 | 2009-06-01 | 2013-11-15 |
| Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women 150 mg, 75 mg, 100 mg - Postmenopausal Osteoporosis | Phase 2 | Completed | Warner Chilcott | 205 | 2009-05-01 | 2015-06-29 |
| A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density Alendronate, Denosumab, Placebo - Postmenopausal Osteoporosis | Phase 2 | Completed | Amgen | 247 | 2006-05-01 | 2014-07-25 |
| Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women synthetic hPTH 1-34 - Postmenopausal Osteoporosis, Osteoporosis | Phase 2 | Completed | Massachusetts General Hospital | 80 | 2004-05-01 | 2013-10-30 |
| Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis. Bazedoxifene, Placebo - Postmenopausal Osteoporosis | Phase 2 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 375 | 2003-08-01 | 2007-12-20 |
Osteoporosis, Postmenopausal (14) · Osteoporosis (6) · Bone Diseases, Metabolic (3) · Bone Diseases (1) · Bone Resorption (1) · Crisponi syndrome (1) · Sclerosteosis (1)
Metabolic Diseases (14) · Musculoskeletal Diseases (14) · Nutritional and Metabolic Diseases (14) · Bone Diseases (13) · Bone Diseases, Metabolic (11) · Osteoporosis (8)
Denosumab (4) · Alendronate (3) · Teriparatide (2) · Calcium Carbonate (1) · Cholecalciferol (1) · Deferasirox (1) · JTT 305 (1) · Zoledronic Acid (1) · bazedoxifene (1) · parathyroid hormone (1-31) (1) · romosozumab (1)
Amgen (3) · Angitia Biopharmaceuticals (1) · Fujian Academy of Traditional Chinese Medicine (1) · Massachusetts General Hospital (1) · Merck Sharp & Dohme LLC (1) · Second Affiliated Hospital of Soochow University (1) · Shanghai JMT-Bio Inc. (1) · Shenzhen Salubris Pharmaceuticals Co., Ltd. (1) · Transcenta Therapeutics (Hangzhou) Co., Ltd. (1) · Unigene Laboratories Inc. (1) · Warner Chilcott (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1)
China (4) · United States (3) · Argentina (1) · Denmark (1) · Estonia (1) · Poland (1) · Ukraine (1)
Bettina S Nedergaard, MD (1) · Chantell Wilson, PhD (1) · Christence S Teglbjaerg, MD (1) · Ivo Valter, MD (1) · Joel S. Finkelstein, MD (1) · Peter Alexandersen, MD (1) · Ricardo Dent-Acosta, MD (1) · Robert M. Neer, MD (1) · Weibo Xia (1) · Weibo Xia, Prof. (1) · You-Jia Xu, Ph.D,M.D. (1)
PMID 20839291, PMID 21111078, PMID 23234813, PMID 23719683, PMID 24382002, PMID 26556736, PMID 33606045, PMID 34530172, PMID 40686685
2008 (1), 2009 (1), P50AR044855 (1)